Public Sector Pension Investment Board Acquires 22,039 Shares of Qiagen (NYSE:QGEN)

Public Sector Pension Investment Board increased its holdings in Qiagen (NYSE:QGEN) by 23.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,032 shares of the company’s stock after purchasing an additional 22,039 shares during the period. Public Sector Pension Investment Board’s holdings in Qiagen were worth $5,232,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Nuance Investments LLC grew its position in shares of Qiagen by 17.3% in the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock valued at $216,606,000 after purchasing an additional 778,005 shares during the last quarter. Earnest Partners LLC boosted its stake in Qiagen by 11.1% during the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock valued at $156,441,000 after purchasing an additional 379,679 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in Qiagen by 12.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock valued at $133,292,000 after buying an additional 353,280 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Qiagen by 62.6% in the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock valued at $117,329,000 after buying an additional 991,325 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Qiagen by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock worth $105,726,000 after buying an additional 324,417 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

QGEN has been the topic of several research analyst reports. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 17th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Price Performance

Shares of Qiagen stock opened at $43.43 on Monday. The firm has a market cap of $9.91 billion, a P/E ratio of 111.36, a price-to-earnings-growth ratio of 3.37 and a beta of 0.41. The firm’s 50-day simple moving average is $43.22 and its 200-day simple moving average is $43.70. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.